NICE asks Novartis to pony up more information on Xolair for hives

Courtesy of Genentech/Novartis

The U.K.'s cost-effectiveness gatekeepers have flip-flopped on Novartis' ($NVS) Xolair before, withdrawing support for the drug in 2012 before expanding its approval for asthma the following year. Now, the National Institute for Health and Care Excellence (NICE) is asking the drugmaker to pony up more data on Xolair as a treatment for chronic hives in kids.

The agency decided "there were still questions to be answered" about the drug's cost-effectiveness after an independent appraisal committee weighed in on the drug. NICE is looking for more details and analysis, Health Technology Evaluation Centre Director Carole Longson said.

Novartis, which co-developed Xolair with Roche's ($RHHBY) Genentech unit, has until Dec. 9 to turn in the new data.

Xolair snagged approval earlier this year in Europe and the U.S. to treat chronic hives. In the U.K., a 24-week course of the drug for hives adds up to more than £3,000, Pharmafile notes.

Winning the U.K. cost watchdog's stamp of approval is critical for Novartis as it eyes a lucrative dermatology market and bigger sales for Xolair. The drug brought in $613 million last year in outside-the-U.S. sales for asthma, and an expanded indication for hives could add about $500 million to Novartis' stockpile. David Epstein, who heads up Novartis Pharmaceuticals, told analysts at a healthcare conference in March that dermatology represents a $2 billion to $3 billion opportunity for Novartis, according to PMLive.

Meanwhile, Novartis is facing some regulatory pushback for Xolair as an asthma treatment. The FDA in September slapped the drug with product label warnings about cardiovascular risks. That decision was based on data from a 5-year study comparing Xolair with placebo, which showed that the drug may increase the risk of clots, hearts attacks, mini-strokes and chest pain. But due to study weaknesses the FDA could not quantify the risks, the agency said at the time of its decision.

- see the NICE consultation document
- read the Pharmafile story
- here's the PMLiVE article

Special Report: The top 10 pharma companies by 2013 revenue - Novartis - Roche

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.